Lineage Cell Therapeutics Inc (LCTX)
1.11
+0.01
(+0.91%)
USD |
NYAM |
Apr 25, 16:00
1.17
+0.06
(+5.41%)
After-Hours: 20:00
Lineage Cell Therapeutics Revenue (TTM): 8.945M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 8.945M |
| September 30, 2023 | 8.772M |
| June 30, 2023 | 10.52M |
| March 31, 2023 | 11.85M |
| December 31, 2022 | 14.70M |
| September 30, 2022 | 13.75M |
| June 30, 2022 | 12.95M |
| March 31, 2022 | 8.84M |
| December 31, 2021 | 3.896M |
| September 30, 2021 | 3.102M |
| June 30, 2021 | 1.242M |
| March 31, 2021 | 0.90M |
| December 31, 2020 | 0.773M |
| September 30, 2020 | 1.439M |
| June 30, 2020 | 1.314M |
| March 31, 2020 | 1.465M |
| December 31, 2019 | 1.478M |
| September 30, 2019 | 0.817M |
| June 30, 2019 | 0.864M |
| March 31, 2019 | 1.22M |
| December 31, 2018 | 1.416M |
| September 30, 2018 | 1.814M |
| June 30, 2018 | 2.013M |
| March 31, 2018 | 1.788M |
| December 31, 2017 | 1.792M |
| Date | Value |
|---|---|
| September 30, 2017 | 1.981M |
| June 30, 2017 | 1.908M |
| March 31, 2017 | 2.033M |
| December 31, 2016 | 2.24M |
| September 30, 2016 | 2.037M |
| June 30, 2016 | 2.487M |
| March 31, 2016 | 2.553M |
| December 31, 2015 | 2.532M |
| September 30, 2015 | 2.422M |
| June 30, 2015 | 2.125M |
| March 31, 2015 | 2.02M |
| December 31, 2014 | 1.946M |
| September 30, 2014 | 2.761M |
| June 30, 2014 | 2.772M |
| March 31, 2014 | 2.828M |
| December 31, 2013 | 2.861M |
| September 30, 2013 | 2.119M |
| June 30, 2013 | 2.127M |
| March 31, 2013 | 1.965M |
| December 31, 2012 | 1.693M |
| September 30, 2012 | 0.059M |
| June 30, 2012 | 0.6586M |
| March 31, 2012 | 1.078M |
| December 31, 2011 | 1.651M |
| September 30, 2011 | 1.877M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
0.773M
Minimum
Dec 2020
14.70M
Maximum
Dec 2022
5.664M
Average
3.102M
Median
Sep 2021
Revenue (TTM) Benchmarks
| Acumen Pharmaceuticals Inc | -- |
| Sarepta Therapeutics Inc | 1.243B |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.202M |
| IGC Pharma Inc | 1.216M |